Polymer nanoparticles delivering sustained-release rapamycin showed strong suppression of ocular blood-vessel growth in animal models of wet age-related macular degeneration. The platform used a chitosan-coated nanoparticle formulation and reduced pathological vessel formation while also decreasing inflammation and retinal damage. The study is framed as preclinical evidence for a long-acting approach that targets angiogenesis and the downstream tissue injury cascade, rather than only measuring vascular endpoints. It also emphasizes sustained release—an important design parameter for chronic retinal disorders. While the work remains in animals, it provides a mechanistic and translational candidate for developers seeking non-invasive dosing strategies for retinal neovascular disease.
Get the Daily Brief